PPT-Comparison of NNRTI vs NNRTI

ENCORE EFV vs RPV ECHOTHRIVE STAR EFV vs ETR SENSE DOR vs EFV DRIVEAHEAD Design Objective Non inferiority of EFV 400 mg at W48 HIV RNA lt 200 c mL by modified intention to treat analysis all randomised participants who received at least . monotherapy. MONOI. MONET. PROTEA. DRV600. Design. Objective. Non inferiority in the proportion of patients with HIV-1 RNA < 50 c/. mL. at W48 (ITT analysis, missing/discontinuation/switch= failure, snapshot algorithm. Vincent Marconi, . MD. Outline. Transmitted Drug Resistance. Acquired Drug Resistance. Transmitted Drug Resistance. Europe. North America. Japan. Australia. Europe. 23K . pts. from 75 studies in 20 countries. EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . Study. NVP vs ATV/r . ARTEN . EFV vs ATV/r . A5202. DOR vs DRV/r. DRIVE-FORWARD. Design. Objective. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, . Switch to DTG + RPV. SWORD. . Study. Switch to CAB LA + RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA + rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Camille Angle, Meagan Bardan, Hanna Schimjawicz and Sean Tabarah. PHM142 Fall . 2018. Instructor: . Ms. Maya Latif. Coordinator: Dr. J. Henderson. HIV Attachment and Penetration. Wilen, C. B., Tilton, J. C., & Doms, R. W. D. (2012). HIV: Cell binding and entry. . HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action. IAS 2017 . Paris . 24. th. July 2017. Modelling the cost and cost-effectiveness of responses to . HIV drug resistance. SWORD. . Study. Switch to CAB LA RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objectives. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (lower margin of the 95% CI for the difference = - 10%, . DRIVE-SHIFT. . Study. . Design. Endpoints. Primary: % of patients maintaining HIV RNA < 50 c/mL (ITT-snapshot) ; non-inferiority of DOR/3TC/TDF at W48 (and at W24) compared to continuation of . cART. p. resented by. NCATEC. March . 18, . 2014. David . Wohl. , MD. Joe . Eron. , MD. Conference Call Line: (. 919) 962-. 2731 - Please mute your phones.. CROI 2014 Update: Implications for the Future of HIV Management. Dr Laura Oyiengo. NATIONAL AIDS STI CONTROL PROGRAM. MOH. BACKGROUND. As a country with the fourth largest Pediatric HIV epidemic in the world, Pediatricians need to be involved in programming, decision making and management of children and adolescent living with HIV and also in PMTCT programming.. Madeline Droney, PharmD. In it for the Long-Haul. Long-Acting Injectables in HIV Treatment. Conflict of Interest. The presenters report no conflict of interest. Review the treatment recommendations for human immunodeficiency virus (HIV) infection. R. egimens . m. ay Need . O. ptimization for Youth Failing ART. V Kouamou. , J Manasa, D Katzenstein, A McGregor, CE Ndhlovu, A T Makadzange, PESU Study Team. C. onflict . of . Interest . D. eclaration.